These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 7577037)

  • 1. CPT-11 (irinotecan) in the treatment of colorectal cancer.
    Armand JP; Ducreux M; Mahjoubi M; Abigerges D; Bugat R; Chabot G; Herait P; de Forni M; Rougier P
    Eur J Cancer; 1995; 31A(7-8):1283-7. PubMed ID: 7577037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current status of colorectal cancer: CPT-11 (irinotecan), a therapeutic innovation.
    Cunningham D
    Eur J Cancer; 1996; 32A Suppl 3():S1-8. PubMed ID: 8943658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of irinotecan in colorectal cancer.
    Saltz LB
    Curr Oncol Rep; 1999; 1(2):155-60. PubMed ID: 11122813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile.
    Rougier P; Bugat R
    Semin Oncol; 1996 Feb; 23(1 Suppl 3):34-41. PubMed ID: 8633252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CPT-11: an original spectrum of clinical activity.
    Rothenberg ML
    Semin Oncol; 1996 Feb; 23(1 Suppl 3):21-6. PubMed ID: 8633249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of CPT-11 (irinotecan) as a single agent in metastatic colorectal cancer.
    Shimada Y; Rougier P; Pitot H
    Eur J Cancer; 1996; 32A Suppl 3():S13-7. PubMed ID: 8943660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topoisomerase I inhibitors in the treatment of colorectal cancer.
    Rothenberg ML; Blanke CD
    Semin Oncol; 1999 Dec; 26(6):632-9. PubMed ID: 10606256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CPT-11 (irinotecan) and 5-fluorouracil: a promising combination for therapy of colorectal cancer.
    Saltz L; Shimada Y; Khayat D
    Eur J Cancer; 1996; 32A Suppl 3():S24-31. PubMed ID: 8943662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.
    Saltz LB; Douillard JY; Pirotta N; Alakl M; Gruia G; Awad L; Elfring GL; Locker PK; Miller LL
    Oncologist; 2001; 6(1):81-91. PubMed ID: 11161231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CPT-11 (irinotecan) in the treatment of colorectal cancer: a new mechanism of action for additional activity.
    Bleiberg H
    Tumori; 1997; 83(1 Suppl):S85-6. PubMed ID: 9154078
    [No Abstract]   [Full Text] [Related]  

  • 11. Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with irinotecan and folinic acid/5-fluorouracil regimens.
    Moehler M; Hoffmann T; Hildner K; Siebler J; Galle PR; Heike M
    Z Gastroenterol; 2002 Dec; 40(12):957-64. PubMed ID: 12564419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and toxicity of irinotecan in patients with colorectal cancer.
    Rothenberg ML
    Semin Oncol; 1998 Oct; 25(5 Suppl 11):39-46. PubMed ID: 9786315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.
    Rougier P; Bugat R; Douillard JY; Culine S; Suc E; Brunet P; Becouarn Y; Ychou M; Marty M; Extra JM; Bonneterre J; Adenis A; Seitz JF; Ganem G; Namer M; Conroy T; Negrier S; Merrouche Y; Burki F; Mousseau M; Herait P; Mahjoubi M
    J Clin Oncol; 1997 Jan; 15(1):251-60. PubMed ID: 8996150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irinotecan in the treatment of colorectal cancer: clinical overview.
    Vanhoefer U; Harstrick A; Achterrath W; Cao S; Seeber S; Rustum YM
    J Clin Oncol; 2001 Mar; 19(5):1501-18. PubMed ID: 11230497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Irinotecan in colorectal cancer].
    Pozzo C; Cassano A; Barone C
    Tumori; 2001; 87(1 Suppl 1):S49-50. PubMed ID: 11300023
    [No Abstract]   [Full Text] [Related]  

  • 16. Update on European adjuvant trials with irinotecan for colorectal cancer.
    Douillard JY; Barbarot V; Bennouna J
    Oncology (Williston Park); 2002 Apr; 16(4 Suppl 3):13-5. PubMed ID: 12014862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations.
    Cerea G; Vaghi M; Ardizzoia A; Villa S; Bucovec R; Mengo S; Gardani G; Tancini G; Lissoni P
    Anticancer Res; 2003; 23(2C):1951-4. PubMed ID: 12820485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective comparison of single-agent chemotherapy with weekly 5-fluorouracil or weekly irinotecan in previously treated patients with metastatic colorectal cancer.
    Lavrenkov K; Man S; Mermershtain W; Cohen Y
    J Chemother; 2002 Feb; 14(1):84-7. PubMed ID: 11892905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CPT-11 in gastrointestinal cancer.
    Bleiberg H
    Eur J Cancer; 1999 Mar; 35(3):371-9. PubMed ID: 10448285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group.
    Van Cutsem E; Blijham GH
    Semin Oncol; 1999 Feb; 26(1 Suppl 5):13-20. PubMed ID: 10213010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.